MiddleEast Blood Glucose Monitoring System Market is expected to reach US$ 140.28 Mn. at a CAGR of 11 during the forecast period 2026. The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region. To know about the Research Methodology:-Request Free Sample Report Blood glucose monitoring tests glucose concentration level in blood using patients’ blood that is tested over a chemically active test-strip. It is the electrical characteristic that helps in determining blood sugar level using glucose monitoring systems. The glucose monitoring systems are portable and have become cost-efficient as well in the last few years. The human body is adapted to release insulin as and when required, depending on the level of glucose present in the blood. These monitoring systems provide information related to the glucose level present in the blood. It helps in determining the next course of action along with being a helping hand in the treatment as well. Real-time information allows patients to monitor their medications as well thereby giving them the space to change the course of treatment accordingly. In the case of insulin, physicians need to be consulted at the time of fluctuations in blood glucose level. The middle-east market for blood glucose monitoring system comprises of patient care setting, testing type, products, application, and geography. Patient care setting has been divided into homecare and hospitals with homecare holding a larger market share. It is the rise in awareness among people related to their health, easier availability of products along with growth in geriatric population has formed some of the major drivers that have led homecare to be the dominant segment. Considering the testing type segment, the fingertip type has held a larger share as compared to the alternate site. Traditional ways of blood testing have been done through fingertips which is easy to access as well. These are some of the factors that have helped fingertip to hold a higher market share. On the basis of product, the market has been segmented into self-monitoring and continuous monitoring systems. Self-monitoring has higher applications across different age groups with more number of people opting for quick detection of blood glucose levels as compared to the older techniques that needed a lot of time. Continuous systems use sensors fitted underneath the skin to monitor continuous changes happening in the blood glucose level. Continuous monitoring systems have a huge scope in the upcoming years and have further accounted one of the highest CAGR as compared to other segments. Middle-East has seen huge growth in terms of infrastructural and healthcare development in the last few years. Companies all over the world are measuring this opportunity and have focused on Middle-east to grow its overall market share. Diabetes has been one of the most widely spread diseases that is expected to spread further resulting in the rapid application of blood glucose monitoring systems in Middle-East.
Blood Glucose Monitoring System Market ,Key Highlights:• Middle-East Blood Glucose Monitoring System market size analysis and forecast • Comprehensive study and analysis of market drivers, restraints, and opportunities influencing the growth of the Middle-East Blood Glucose Monitoring System market • Blood Glucose Monitoring System market segmentation on the basis of product, testing type, patient care setting, application, and geography. • Blood Glucose Monitoring System market strategic analysis with respect to individual growth trends, future prospects along with a contribution of various sub-market stakeholders have been considered under the scope of a study • Blood Glucose Monitoring System market analysis and forecast for major countries has been provided. • Profiling of key industry players, their strategic perspective, market positioning and analysis of core competencies • Competitive landscape of the key players operating in the Blood Glucose Monitoring System market including competitive developments, investments, and strategic expansion
Blood Glucose Monitoring System Market, Research Methodology:The market is estimated by triangulation of data points obtained from various sources and feeding them into a simulation model created individually for each market. The data points are obtained from paid and unpaid sources along with paid primary interviews with key opinion leaders (KOLs) in the market. KOLs from both, demand and supply side were considered while conducting interviews to get an unbiased idea of the market. This exercise was done at a country level to get a fair idea of the market in countries considered for this study. Later this country-specific data was accumulated to come up with regional numbers and then arrive at the market value for Middle-East Blood Glucose Monitoring System market
Some of the key players of the Middle-East Blood Glucose Monitoring System market include:• Abbott Laboratories • Merck • Roche Diagnostics • Amgen • GlaxoSmithKline • Bayer • Sanofi • Gilead Sciences • Boehringer Ingelheim • Takeda Pharmaceuticals
Blood Glucose Monitoring System Market, Key Target Audience:• Blood glucose monitoring systems and related devices manufacturers • Hospitals, diagnostic centers, homecare service providers, and medical colleges • Teaching hospitals and academic medical centers • Suppliers and distributors of blood glucose monitoring systems • Government bodies or municipal corporations
Scope of the Blood Glucose Monitoring System Market Report: Inquire before buyingThe research report segments Middle-East Blood Glucose Monitoring System market based on product, testing site, patient care setting, application and geography.
Blood Glucose Monitoring System Market, By Product:• Self-Monitoring Blood Glucose Systems • Blood Glucose meters • Testing strips • Lancets & Lancing Devices • Continuous Glucose Monitoring Systems o • Sensors • Transmitters • Receivers
Blood Glucose Monitoring System Market, By Testing Site:• Fingertip testing • Alternate Site Testing
Blood Glucose Monitoring System Market, By Patient Care Setting:• Self/Home Care • Hospital & Clinics
Blood Glucose Monitoring System Market, By Application:Type 2 Diabetes • Type 1 Diabetes • Gestational Diabetes
Blood Glucose Monitoring System Market, By Geography:• Middle-East • GCC Countries • Israel • Others
Blood Glucose Monitoring System Market, Geographic Analysis• Breakdown of GCC Countries Blood Glucose Monitoring System market • Breakdown of Israel Blood Glucose Monitoring System market • Breakdown of Others Blood Glucose Monitoring System market
Available CustomizationMaximize Market Research offers customization of reports according to the specific requirement of our clients
Middle-East Blood Glucose Monitoring System Market1. EXECUTIVE SUMMARY 2. RESEARCH METHODOLOGY 2.1. Market Definition 2.2. Market Scope 2.3. Data Sources 3. MARKET VARIABLES SCOPE 3.1. Market Segmentation Scope 3.2. Market Driver Analysis 3.3. Market Restraint Analysis 3.4. Penetration Growth Prospect Mapping 3.5. Market SWOT Analysis, By Factor (political legal, economic and technological) 3.6. Porter’s Five Forces Industry Analysis 3.7. Market Value Chain Analysis 4. PRODUCT ESTIMATES TREND ANALYSIS (2019 – 2026) 4.1. Blood Glucose Monitoring System Market: Product Analysis 4.2. Self-Monitoring Blood Glucose Systems 4.2.1. Self-Monitoring Blood Glucose Systems market, 2019 – 2026 (USD billion) 4.3. Continuous Glucose Monitoring Systems 4.3.1. Continuous Glucose Monitoring Systems market, 2019 – 2026 (USD billion) 5. TESTING SITE ESTIMATES TREND ANALYSIS (2019 – 2026) 5.1. Blood Glucose Monitoring System Market: Testing Site Analysis 5.2. Fingertip 5.2.1. Fingertip market, 2019 – 2026 (USD billion) 5.3. Alternate Site 5.3.1. Alternate Site market, 2019 – 2026 (USD billion) 6. PATIENT CARE SETTING ESTIMATES TREND ANALYSIS (2019 – 2026) 6.1. Blood Glucose Monitoring System Market: Patient Care Setting Analysis 6.2. Self/Home Care 6.2.1. Self/Home Care market, 2019 – 2026 (USD billion) 6.3. Hospital Clinics 6.3.1. Hospital Clinics market, 2019 – 2026 (USD billion) 7. APPLICATION ESTIMATES TREND ANALYSIS (2019 – 2026) 7.1. Blood Glucose Monitoring System Market: Application Analysis 7.2. Type 2 Diabetes 7.2.1. Type 2 Diabetes market, 2019 – 2026 (USD billion) 7.3. Type 1 Diabetes 7.3.1. Type 1 Diabetes market, 2019 – 2026 (USD billion) 7.4. Gestational Diabetes 7.4.1. Gestational Diabetes market, 2019 – 2026 (USD billion) 8. REGIONAL ESTIMATES TREND ANALYSIS BY PRODUCT, TESTING TYPE, PATIENT CARE SETTING AND APPLICATION (2019 – 2026) 8.1. Blood Glucose Monitoring System market share by country, 2016 2025 8.2. GCC Countries 8.2.1. China Blood Glucose Monitoring System market, 2019 – 2026 (USD billion) 8.3. Israel 8.3.1. Japan Blood Glucose Monitoring System market, 2019 – 2026 (USD billion) 8.4. Others 8.4.1. Others Blood Glucose Monitoring System market, 2019 – 2026 (USD billion) 9. MARKET COMPETITION ANALYSIS 9.1. Strategy Framework 9.2. Company Profiles 9.2.1. Abbott Laboratories 22.214.171.124. Company Overview 126.96.36.199. Financial Performance 188.8.131.52. Product Benchmarking 184.108.40.206. Strategic Initiatives 9.2.2. Merck 220.127.116.11. Company Overview 18.104.22.168. Financial Performance 22.214.171.124. Product Benchmarking 126.96.36.199. Strategic Initiatives 9.2.3. Roche Diagnostics 188.8.131.52. Company Overview 184.108.40.206. Financial Performance 220.127.116.11. Product Benchmarking 18.104.22.168. Strategic Initiatives 9.2.4. Amgen 22.214.171.124. Company Overview 126.96.36.199. Financial Performance 188.8.131.52. Product Benchmarking 184.108.40.206. Strategic Initiatives 9.2.5. GlaxoSmithKline 220.127.116.11. Company Overview 18.104.22.168. Financial Performance 22.214.171.124. Product Benchmarking 126.96.36.199. Strategic Initiatives 9.2.6. Bayer 188.8.131.52. Company Overview 184.108.40.206. Financial Performance 220.127.116.11. Product Benchmarking 18.104.22.168. Strategic Initiatives 9.2.7. Sanofi 22.214.171.124. Company Overview 126.96.36.199. Financial Performance 188.8.131.52. Product Benchmarking 184.108.40.206. Strategic Initiatives 9.2.8. Gilead Sciences 220.127.116.11. Company Overview 18.104.22.168. Financial Performance 22.214.171.124. Product Benchmarking 126.96.36.199. Strategic Initiatives 9.2.9. Boehringer Ingelheim 188.8.131.52. Company Overview 184.108.40.206. Financial Performance 220.127.116.11. Product Benchmarking 18.104.22.168. Strategic Initiatives 9.2.10. Takeda Pharmaceuticals 22.214.171.124. Company Overview 126.96.36.199. Financial Performance 188.8.131.52. Product Benchmarking 184.108.40.206. Strategic Initiatives